#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Tumor markes in renal cancer: help for diagnosis, prognosis, treatment and follow up


Authors: V. Vít
Authors place of work: Urologická klinika FN Brno
Published in the journal: Urol List 2010; 8(2): 11-15

Summary

The author of this review deals with the issue of localized renal carcinoma in patients undergoing surgical treatment. He outlines some of the prognostic factors – standard clinical and patological features used in clinical practice (symptomatology, TNM clasification, histopatological grade, microvascular invasion) and also some new molecular biological markers currently under investigation (HIF-1α, VEGF, Ki67, p53, CXCR 3, MMP 2, MMP 9, IMP 3). He also deals with the role of DNA microchip technologies in renal tumours research.

Key words:
renal carcinoma, prognostic factors, molecular biological markers, DNA microchip technologies


Zdroje

1. Dušek L, Mužík J, Kukásek M et al. Český národní webový portál epidemiologie nádorů (online). Masarykova univerzita, http://www.svod.cz

2. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183(2): 131–133.

3. Kovacs G. Molecular differential patology of renal cell tumours. Histopathology 1993; 22(1): 1–8.

4. Akhtar M, Kfoury H, Kardar A et al. Sarcomatoid chromophobe cell carcinoma of the kidney. J Urol Pathol 1996; 4: 155–166.

5. Rumpelt HJ, Storkel S, Moll R et al. Bellini duct carcinoma: further evidence for this rare variant of renal cell carcinoma. Histopathology 1991; 18(2): 115–122.

6. Chao D, Zisman A,Pantuck AJ et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002; 167(1): 71–74.

7. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patiens with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20(23): 4559–4566.

8. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer 2009; 115(10 Suppl): 2273–2281.

9. Eggener SE, Yossepowitch O, Pettus JA et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24(19): 3101–3106.

10. Jayson M, Sanders H. Increased incidence of seren dipitously discovered renal cell carcinoma. Urology 1998; 51(2): 203–205.

11. Thompson IM, Peek M. Improvement in survival of patiens with renal cell carcinoma-the role of the serendipitously detected tumor. J Urol 1988; 140(3): 487–490.

12. Ou YC, Yang CR, Ho HC et al. The symptoms of renal cell carcinoma related to patiens survival. J Chin Med Assoc 2003; 66(9): 537–543.

13. Tsui KH, Shvarts O, Smith RB et al. Renal cell carcinoma: prognostic significance of incidentaly detected tumors. J Urol 2000; 163(2): 426–430.

14. Ficarra V, Righetti R, Pilloni S et al. Prognostic factors in patiens with renal cell carcinoma. Retro spective analysis of 675 cases. Eur Urol 2002; 41(2): 1902–1908.

15. Han KR, Bui MH, Pantuck AJ et al. TNM T3a renal cell carcinoma: adrenal gland ivolvement is not the same as renal fat invasion. J Urol 2003; 169(3): 899–903.

16. Moinzadeh A, Libertino JA. Prognostic significance of tumor trombus level in patiens with renal cell carcinoma and venous tumor trombus extensit. Is all T3b the same? J Urol 2004; 171: 598–601.

17. Kim HL, Zisman A, Ham KR et al. Prognostic significance of venous trombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004; 171(2Pt1): 588–591.

18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Patholog 1982; 6(7): 655–663.

19. Cheville JC, Lohse CM, Zincke H et al. Comparison of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612–624.

20. Dekel Y, Koren R, Kugel V et al. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002; 8(2): 129–132.

21. Griffiths DF, Verghese A, Golash A et al. Contribution of grade, vascular invasion and age to outcome in clinically localized renal cell carcinoma. BJU Int 2002; 90(1): 26–31.

22. Dalloglio MF, Antunes AA, Sarkis AS et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 2007; 100(3): 552–555.

23. Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patiens with sarcomatoid renal cell carcinoma. J Urol 2002; 167(1): 65–70.

24. de Peralta-Venturina M, Moch H, Amin M et al Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25(3): 275–284.

25. Amin MB, Tamboli P, Javidan J et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26(3): 281–291.

26. Cheville JC, Blute ML, Zincke H et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166(2): 453–456.

27. Minardi D, Lucarini G, Filosa A et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor -1α in patiens with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Imu nopathol and Pharmacol 2008; 21(2): 447–455.

28. Fidler IJ. Angiogenesis and cancer metastasis. Cancer 2000; 6(suppl 2): 134–141.

29. Klatte T, Seligson DB, LaRochelle J et al. Molecular signatures of localised clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 894–900.

30. Babjuk M, Dušková J, Stolz J et al. Exprese P53 a Ki 67 u pacientů s lokalizovaným renálním karcinomem. Česká urologie 2006; 1: 5–9.

31. Shvarts O, Seligson D, Lam J et al. p53 an independent predictor of tumor recurrence and progression after nephrectomy in patiens with localised renal cell carcinoma. J Urol 2005; 173: 725–728.

32. Crispen PL, Boorjian SA, Lohse CM et al. Predicting dinase progression after nephrectomy for localized renal cell carcinoma: the utilitzy of prognostic models and molecular biomarkers. Cancer 2008; 113: 450–460.

33. Klečka J, Běhounek P, Hora M et al. Nádorové markery v urologii. Lékařské listy 2010; 6: 5–8.

34. Jones J, Pantuck AJ.Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis and treatment selection. Curr Urol Rep 2008; 9(1): 9–14.

35. Slabý O, Svoboda M, Michálek J et al. DNA a mikroRNA čipové technologie v diagnostice a predikci u pacientů s renálním karcinomem. Klinická onkologie 2009; 5: 202–209.

Štítky
Paediatric urologist Urology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#